COVID-19: China approves world's first inhalable vaccine for emergency use
The world's first inhalable COVID-19 vaccine has been approved for emergency use in China.
Developed by Tianjin-based manufacturer CanSino Biologics, the vaccine was approved by China's National Medical Products Administration on Sunday, Reuters reports.
The move would have boosted Cansino's share price by 7% on Monday.
While other vaccines have been given by injections, the new needle-free vaccine can be stored and administered easily using a nebulizer, according to the company.
"The approval will have a positive impact on company performance if the vaccine is subsequently purchased and used by relevant government agencies," CanSino said.
The company also said it is unsure when its vaccine will be on the market, as additional administrative approvals are still required.
China has so far approved eight other locally-made injectable vaccines since 2020.
According to the WHO, more than 3.4 billion doses of COVID-19 vaccine have been administered as of August 31.
READ ALSO: COVID-19 in ChinaSince the outbreak of COVID-19, China continues to experience a steady upsurge in infections.
According to WHO COVID-19 data, from January 3, 2020 to September 2, there were 6,477,468 confirmed cases of COVID-19, with 24,883 deaths.
The southern technology hub of Shenzhen imposed a weekend lockdown in most parts of the city on Saturday, while the southwestern metropolis of Chengdu put its 21 million people under lockdown on Thursday.
Support the integrity and credibility journalism of PREMIUM TIMES Good journalism costs a lot of money. Yet only good journalism can guarantee the possibility of a good society, an accountable democracy and a transparent government. For free and continued access to the best investigative journalism in the country, we ask that you consider providing modest support to this noble endeavour. By contributing to PREMIUM TIMES, you help sustain relevant journalism and keep it free and accessible to everyone.Donate
[embedded content]TEXT ANNOUNCEMENT: Call Willie - +2348098788999
The world's first inhalable COVID-19 vaccine has been approved for emergency use in China.
Developed by Tianjin-based manufacturer CanSino Biologics, the vaccine was approved by China's National Medical Products Administration on Sunday, Reuters reports.
The move would have boosted Cansino's share price by 7% on Monday.
While other vaccines have been given by injections, the new needle-free vaccine can be stored and administered easily using a nebulizer, according to the company.
"The approval will have a positive impact on company performance if the vaccine is subsequently purchased and used by relevant government agencies," CanSino said.
The company also said it is unsure when its vaccine will be on the market, as additional administrative approvals are still required.
China has so far approved eight other locally-made injectable vaccines since 2020.
According to the WHO, more than 3.4 billion doses of COVID-19 vaccine have been administered as of August 31.
READ ALSO: COVID-19 in ChinaSince the outbreak of COVID-19, China continues to experience a steady upsurge in infections.
According to WHO COVID-19 data, from January 3, 2020 to September 2, there were 6,477,468 confirmed cases of COVID-19, with 24,883 deaths.
The southern technology hub of Shenzhen imposed a weekend lockdown in most parts of the city on Saturday, while the southwestern metropolis of Chengdu put its 21 million people under lockdown on Thursday.
Support the integrity and credibility journalism of PREMIUM TIMES Good journalism costs a lot of money. Yet only good journalism can guarantee the possibility of a good society, an accountable democracy and a transparent government. For free and continued access to the best investigative journalism in the country, we ask that you consider providing modest support to this noble endeavour. By contributing to PREMIUM TIMES, you help sustain relevant journalism and keep it free and accessible to everyone.Donate
[embedded content]TEXT ANNOUNCEMENT: Call Willie - +2348098788999
What's Your Reaction?
